- Home
- SRZN vs ABOS Comparison
SRZN vs ABOS Comparison
Compare SRZN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | ABOS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRZN | ABOS |
|---|---|---|
| Price | $21.94 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $38.50 | $7.67 |
| AVG Volume (30 Days) | 108.1K | ★ 167.9K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,604,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $0.86 |
| 52 Week High | $24.94 | $2.46 |
Technical Indicators
Market Signals| Indicator | SRZN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 50.02 |
| Support Level | $21.03 | $1.90 |
| Resistance Level | $23.42 | $2.39 |
| Average True Range (ATR) | 1.89 | 0.14 |
| MACD | -0.33 | -0.01 |
| Stochastic Oscillator | 39.03 | 24.43 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.